From March 2021 the Ministry of Health and Welfare in South Korea will grant expanded reimbursement for the acute HAE treatment Firazyr.
The ministry will expand the insurance benefits for Firazyr to two doses per patient from the existing one-dose regimen. The expanded insurance benefit will allow patients with confirmed HAE due to a deficiency of a C1-esterase inhibitor to receive reimbursement for up to two doses.
“As the only treatment for HAE acute seizures in Korea, we are very pleased that the reimbursement has improved the treatment environment for patients with HAE,” says Ji Chang-duk, head of Takeda Pharmaceutical Korea’s genetic disease business unit. “Patients with HAE, who have a hard time carrying out their daily lives due to unexpected seizures, will now have an opportunity to respond effectively to emergencies.”
(Source: Takeda via koreabiomed.com)